Investment firm Leerink Partners has upgraded the stock rating of cancer screening company NeoGenomics from "Market Perform" to "Outperform," while significantly raising its target price from $12 to $25, demonstrating strong confidence in the company's prospects in the field of tumor genetic testing.

Investment firm Leerink Partners has upgraded the stock rating of cancer screening company NeoGenomics from "Market Perform" to "Outperform," while significantly raising its target price from $12 to $25, demonstrating strong confidence in the company's prospects in the field of tumor genetic testing.

老虎证券2026/04/29 11:39

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This rating adjustment reflects analysts' reassessment of NeoGenomics' business transformation and growth potential. The significant increase in the target price indicates that Leerink Partners believes the company's current stock price does not fully reflect its future value, and it is expected that the stock price will have substantial upside potential.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

You may also like

Trending news

Crypto prices